Swedish drug-delivery company Nanexa announced a licensing agreement with Novo Nordisk on 25 September 2026 covering injectable formulations and delivery systems. The deal was reported by Cnbc TOP, Finnhub, and Marketwatch TOP. Marketwatch TOP reported the agreement is valued at over $1 billion, making it a material transaction for a microcap firm. Novo Nordisk is widely known for its GLP-1 injectable products, including Wegovy.
Nanexa shares rose more than 150% following the announcement, as reported by Cnbc TOP and Finnhub. The move represented a sharp single-session gain for the Stockholm-listed microcap.
Nanexa is the Swedish drug-delivery company whose injectable formulation technology is the subject of the license. Novo Nordisk — listed as NVO in the US and NOVO B on the Copenhagen exchange — is the acquiring licensee and counterparty to the agreement; Marketwatch TOP noted the deal follows a recent disappointing capital-markets day for the Danish pharmaceutical group.
No official regulatory statements or government responses to the deal were reported in the cluster.
Sources: Cnbc TOP, CNBC, Marketwatch TOP